Granules India Q4FY26 revenue jumps 23% to Rs 14,706 million; FY26 revenue at Rs 53,656 million
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Subscribe To Our Newsletter & Stay Updated